Non-clear cell renal cell carcinoma, part 2: therapy.
作者： Toni K Choueiri , Michelle S Hirsch , Lauren C Harshman , Loana B Valenca
DOI:
关键词:
摘要: Non-clear cell renal carcinomas (RCCs) represent a heterogeneous group of diseases with distinct molecular drivers, histologies, and clinical outcomes. Their low incidence heterogeneity have resulted in lack studies that address the optimal strategies for each subtype. This article (the second 2-part series) reviews current targeted therapies approved RCC, such as vascular endothelial growth factor receptor tyrosine kinase inhibitors mammalian target rapamycin inhibitors. Ongoing will provide more information regarding role these agents non-clear RCC. Ultimately, enhanced understanding genetic triggers development tailored treatments remain imperative to improve outcomes
参考文章(90)
Alan Yagoda, Daniel Petrylak, Seth Thompson, Cytotoxic chemotherapy for advanced renal cell carcinoma. Urologic Clinics of North America. ,vol. 20, pp. 303- 321 ,(1993) , 10.1016/S0094-0143(21)00489-4
Patrick Schöffski, Jorge A. Garcia, Walter M. Stadler, Thierry Gil, Eric Jonasch, Scott T. Tagawa, Melanie Smitt, Xinqun Yang, Kelly S. Oliner, Abraham Anderson, Min Zhu, Fairooz Kabbinavar, A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma BJUI. ,vol. 108, pp. 679- 686 ,(2011) , 10.1111/J.1464-410X.2010.09947.X
Andrew J. Wagner, John M. Goldberg, Steven G. DuBois, Edwin Choy, Lee Rosen, Alberto Pappo, James Geller, Ian Judson, David Hogg, Neil Senzer, Ian J. Davis, Feng Chai, Carol Waghorne, Brian Schwartz, George D. Demetri, Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. ,vol. 118, pp. 5894- 5902 ,(2012) , 10.1002/CNCR.27582
Ayal A Aizer, Yuksel Urun, Rana R McKay, Adam S Kibel, Paul L Nguyen, Toni K Choueiri, None, Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC) BJUI. ,vol. 113, ,(2014) , 10.1111/BJU.12442
Akinori Sato, Takako Asano, Keiichi Ito, Makoto Sumitomo, Tomohiko Asano, Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically BJUI. ,vol. 109, pp. 1258- 1268 ,(2012) , 10.1111/J.1464-410X.2011.10533.X
Robert J. Motzer, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy Kuzel, Michael Roger Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theodore F. Logan, Kim Allyson Margolin, Elizabeth R. Plimack, Ian Waxman, Alexandre Lambert, Hans J. Hammers, Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. Journal of Clinical Oncology. ,vol. 32, pp. 5009- 5009 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.5009
Daniel C Cho, Jeffrey Alan Sosman, Mario Sznol, Michael S Gordon, Antoine Hollebecque, Omid Hamid, David F McDermott, Jean-Pierre Delord, Ina Park Rhee, Ahmad Mokatrin, Marcin Kowanetz, Roel Peter Funke, Gregg Daniel Fine, Thomas Powles, None, Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. ,vol. 31, pp. 4505- 4505 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.4505
Y. Koh, H.Y. Lim, J.H. Ahn, J.-L. Lee, S.Y. Rha, Y.J. Kim, T.M. Kim, S.-H. Lee, Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma Annals of Oncology. ,vol. 24, pp. 1026- 1031 ,(2013) , 10.1093/ANNONC/MDS582
Lauren C. Harshman, Toni K. Choueiri, Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer Journal. ,vol. 19, pp. 316- 323 ,(2013) , 10.1097/PPO.0B013E31829E3C9A
Dae Y. Kim, Jose A. Karam, Christopher G. Wood, Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy World Journal of Urology. ,vol. 32, pp. 631- 642 ,(2014) , 10.1007/S00345-014-1293-6